Abbott Laboratories (ABT) Share-based Compensation (2009 - 2026)

Abbott Laboratories has disclosed Share-based Compensation across 18 years of filings, most recently posting $317.0 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $317.0 million, up 9.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $692.0 million (up 5.17% YoY), and the FY2025 annual result was $664.0 million, down 1.34% from the prior year.
• Share-based Compensation came in at $317.0 million for Q1 2026 at Abbott Laboratories, up from $113.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $317.0 million in Q1 2026 to a low of $111.0 million in Q4 2024.
• The 5-year median for Share-based Compensation is $132.0 million (2023), against an average of $175.5 million.
• Across the five-year window, Share-based Compensation declined 7.87% in 2023 and increased 9.69% in 2026, its largest moves.
• Abbott Laboratories' Share-based Compensation stood at $115.0 million in 2022, then slipped by 0.87% to $114.0 million in 2023, then dropped by 2.63% to $111.0 million in 2024, then climbed by 1.8% to $113.0 million in 2025, then surged by 180.53% to $317.0 million in 2026.
• The last three Share-based Compensation figures came in at $317.0 million (Q1 2026), $113.0 million (Q4 2025), and $120.0 million (Q3 2025), per Business Quant data.